In female pattern hair loss primarily driven by dehydroepiandrosterone sulfate (DHEA‑S) affecting hair shaft thickness, what is the clinical value of measuring serum prolactin, total testosterone, and DHEA‑S?

Clinical Value of Measuring Prolactin, Total Testosterone, and DHEA-S in Female Pattern Hair Loss

Measuring prolactin, total testosterone, and DHEA-S is recommended but optional in female pattern hair loss (FPHL), serving primarily to identify underlying androgen excess or other endocrine disorders that may require specific treatment, rather than to diagnose FPHL itself, which remains a clinical diagnosis. 1

Understanding the Premise of Your Question

Your question assumes DHEA-S primarily drives FPHL through effects on hair thickness. However, this premise requires important clarification: the relationship between androgens (including DHEA-S) and FPHL is neither consistent nor clear. Most women with FPHL have normal circulating androgen levels, and the condition has been documented even in women with complete androgen deficiency or absent androgen receptors 1. This fundamentally challenges the assumption that DHEA-S is the primary driver in most cases.

The Guideline-Based Approach to Hormonal Testing

Mandatory vs. Optional Testing

The 2019 Androgen Excess and PCOS Society guidelines provide clear direction 1:

• Mandatory: Assessment for androgen excess in ALL patients with FPHL
• Optional but recommended: Prolactin, vitamin D, iron, zinc, and thyroid hormones

Specific Hormonal Measurements Recommended

When evaluating androgens, the guidelines specify 1:

• Total testosterone using high-quality assay (preferably LC/MS or immunoassay with extraction/purification)
• Free testosterone (via equilibrium dialysis, ultracentrifugation, or estimated using SHBG)
• DHEA-S is mentioned as part of the androgen panel but not specifically emphasized

Prolactin measurement is explicitly listed as optional but recommended to rule out other conditions that may affect hair regrowth 1.

Clinical Value of Each Test

Total Testosterone

• Primary value: Identifies hyperandrogenism requiring specific treatment
• Clinical context: Only 6.8% of FPHL patients show abnormal testosterone levels 2
• Treatment implications: Guides use of antiandrogens or 5α-reductase inhibitors when elevated or when severe hair loss present 1

DHEA-S

• Primary value: Detects adrenal androgen excess
• Clinical context: Only 4.5% of FPHL patients show abnormal DHEA-S 2
• Emerging evidence: One study found DHEA-S significantly associated with FPHL 3, though this contradicts the guideline consensus that most patients have normal levels
• Practical limitation: Normal DHEA-S does NOT exclude FPHL or indicate lack of androgen involvement at the follicular level

Prolactin

• Primary value: Identifies hyperprolactinemia as a treatable cause of hair loss
• Clinical context: Can be elevated after TRH stimulation in some FPHL patients 4
• Mechanism: Prolactin has androgen-stimulating effects that may contribute to FPHL 4
• Treatment implications: If elevated, treating hyperprolactinemia may improve hair loss

Critical Clinical Pitfalls

The Peripheral Hyperandrogenism Problem

The most important caveat: Normal serum androgen levels do NOT exclude androgen-mediated hair loss. Recent evidence shows that 3α-androstanediol glucuronide (3α-diol G), a marker of peripheral androgen metabolism, is significantly elevated in FPHL patients even when standard androgens are normal 2. This metabolite showed:

• 82% sensitivity and 73% specificity for FPHL
• Positive correlation with disease severity
• Superior diagnostic accuracy compared to testosterone or DHEA-S

This explains why FPHL can occur with normal circulating androgens—the problem is often at the tissue level, not systemic.

When NOT to Over-Interpret Results

Isolated FPHL with normal androgen levels should NOT be considered a sign of hyperandrogenism 1. The diagnosis of FPHL is primarily clinical, not biochemical 1.

Algorithmic Approach to Testing

1. Clinical diagnosis first: Establish FPHL based on pattern (centrifugal mid-scalp expansion or frontal accentuation), miniaturization without true baldness, preserved follicular ostia 1

2. Screen for androgen excess in ALL patients:

   • Total testosterone (high-quality assay)
   • Free testosterone or calculate free androgen index using SHBG
   • DHEA-S
   • Prolactin

3. Interpret results:

   • If androgens elevated: Investigate for PCOS, adrenal disorders, or androgen-secreting tumors
   • If prolactin elevated: Evaluate for prolactinoma or other causes of hyperprolactinemia
   • If all normal: Proceed with treatment based on clinical severity alone

4. Treatment decisions 1:

   • Start with topical minoxidil 5% for ALL patients
   • Add antiandrogens (spironolactone 100-200 mg/d) or 5α-reductase inhibitors (finasteride 2.5-5 mg/d) if:
     • Severe hair loss present, OR
     • Documented hyperandrogenism present
   • Ensure contraception in reproductive-age women receiving systemic antiandrogens

The Bottom Line on Clinical Value

These tests identify the minority of FPHL patients (~20-30%) who have underlying endocrine disorders requiring specific treatment 1. Their value is NOT in diagnosing FPHL (which is clinical) or predicting treatment response in normoandrogenic patients, but rather in:

• Detecting treatable causes of androgen excess (PCOS, adrenal disorders)
• Identifying hyperprolactinemia
• Guiding decisions about systemic antiandrogen therapy
• Ruling out other endocrine contributors to hair loss

The majority of FPHL patients will have normal results, which does not negate the diagnosis or preclude treatment with minoxidil and potentially antiandrogens based on clinical severity alone.